Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orantinib

Drug Profile

Orantinib

Alternative Names: SU 006668; SU 6668; TSU-68

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Taiho Pharmaceutical
  • Class Antineoplastics; Indoles; Propionic acids; Pyrroles; Small molecules
  • Mechanism of Action Fibroblast growth factor inhibitors; Platelet-derived growth factor inhibitors; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer
  • Discontinued Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Jul 2014 Taiho Pharmaceutical terminates the phase III ORIENTAL trial for liver cancer (unresectable disease; combination therapy) in Japan, South Korea & Taiwan (NCT01465464)
  • 18 Feb 2014 Taiho Pharmaceutical completes enrolment in the phase III ORIENTAL trial for liver cancer (unresectable disease; combination therapy) in Japan, South Korea & Taiwan (NCT01465464)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top